The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9
Abstract
The past decade has been one of rapid innovation in genome-editing technology. The opportunity now exists for investigators to manipulate virtually any gene in a diverse range of cell types and organisms with targeted nucleases designed with sequence-specific DNA-binding domains. The rapid development of the field has allowed for highly efficient, precise, and now cost-effective means by which to generate human and animal models of disease using these technologies. This review will outline the recent development of genome-editing technology, culminating with the use of CRISPR-Cas9 to generate novel mammalian models of disease. While the road to using this same technology for treatment of human disease is long, the pace of innovation over the past five years and early successes in model systems build anticipation for this prospect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Challenges with ZFNs include design and engineering of the ZFP for high-affinity binding of the desired sequence, which can prove non-trivial (Ramirez et al., 2008). Also, not all sequences are available for ZFP binding, so site selection is limited. Using open-source ZFP domains, sites could be targeted only every 200-bps in a random DNA sequence (Gupta & Musunuru, 2014).”
From Delivering CRISPR: a review of the challenges and approaches (2018) · cites this paper as Gupta & Musunuru, 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
DNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.04.025 · Cited by 3,495
High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292 · cited 3×
“…highly repetitive nature of the TALENs may impair their ability to be packaged and delivered by some viral vectors (42), though this can apparently be overcome by diversifying the coding sequences of the TALE repeats (43). have been reported for which no off-target activity is detectable (55–60).”
InfluentialA TALE nuclease architecture for efficient genome editing
Miller, J. C., Tan, S., Qiao, G., Barlow, K. A., Wang, J., Xia, D. F., Meng, X., Paschon, D. E., Leung, E., Hinkley, S. J., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1755 · Cited by 2,098
Improving CRISPR-Cas nuclease specificity using truncated guide RNAs
Fu, Y., Sander, J. D., Reyon, D., Cascio, V. M., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2808 · Cited by 1,993 · cited 1×
“Another strategy to reduce off-target effects is to reduce the length of the protospacer portion of the guide RNA, which makes it less tolerant of mismatches and thus can preserve the on-target efficacy while reducing off-target mutagenesis (62).”
Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease
Cho, S. W., Kim, S., Kim, J. M., & Kim, J.-S. (2013) · Nature Biotechnology · doi:10.1038/nbt.2507 · Cited by 1,863
Research works printed but not linked: 60
- 10.1038/317230a0 · DOI · Paper page
- 10.1016/0092-8674(87)90646-5 · DOI · Paper page
- 10.1093/nar/gki324 · DOI · Paper page
- 10.1016/j.ccr.2013.12.007 · DOI · Paper page
- 10.1038/nrg2842 · DOI · Paper page
- 10.1073/pnas.91.13.6064 · DOI · Paper page
- 10.1038/mt.2009.304 · DOI
- 10.1016/j.cell.2011.06.019 · DOI · Paper page
- 10.1038/nmeth.1653 · DOI · Paper page
- 10.1038/nature03556 · DOI · Paper page
- 10.1038/nmeth0508-374 · DOI · Paper page
- 10.1016/j.molcel.2008.06.016 · DOI · Paper page
- 10.1038/nprot.2009.98 · DOI · Paper page
- 10.1038/nmeth.1542 · DOI · Paper page
- 10.1038/nmeth.1994 · DOI
- 10.1101/gr.143693.112 · DOI
- 10.1038/nbt.1562 · DOI · Paper page
- Gabriel, 2011, Nat Biotechnol., 29, 816, 10.1038/nbt.1948 · DOI · Paper page
- Szczepek, 2007, Nat Biotechnol., 25, 786, 10.1038/nbt1317 · DOI · Paper page
- 10.1126/science.1178817 · DOI · Paper page
- 10.1126/science.1178811 · DOI · Paper page
- 10.1073/pnas.1013133107 · DOI · Paper page
- Streubel, 2012, Nat Biotechnol., 30, 593, 10.1038/nbt.2304 · DOI · Paper page
- 10.1038/ncomms1962 · DOI · Paper page
- 10.1534/genetics.110.120717 · DOI · Paper page
- 10.1093/nar/gkq704 · DOI · Paper page
- Hockemeyer, 2011, Nat Biotechnol., 29, 731, 10.1038/nbt.1927 · DOI · Paper page
- 10.1038/nbt.2170 · DOI · Paper page
- 10.1093/nar/gkr218 · DOI · Paper page
- Kim, 2013, Nat Biotechnol., 31, 251, 10.1038/nbt.2517 · DOI · Paper page
- 10.1038/nmeth.2845 · DOI · Paper page
- 10.1016/j.stem.2014.06.016 · DOI · Paper page
- 10.1093/nar/gkt555 · DOI · Paper page
- 10.1126/science.1246981 · DOI · Paper page
- 10.1038/nature13166 · DOI · Paper page
- 10.1073/pnas.1323941111 · DOI
- 10.1038/nmeth.2681 · DOI · Paper page
- 10.1093/nar/gkt714 · DOI · Paper page
- 10.1101/gr.162339.113 · DOI · Paper page
- 10.1016/j.cell.2013.08.021 · DOI · Paper page
- Guilinger, 2014, Nat Biotechnol., 32, 577, 10.1038/nbt.2909 · DOI · Paper page
- 10.1126/science.1172447 · DOI · Paper page
- 10.1371/journal.pone.0008870 · DOI · Paper page
- 10.1038/nbt.1940 · DOI · Paper page
- Li, 2013, Nat Biotechnol., 31, 681, 10.1038/nbt.2661 · DOI · Paper page
- 10.1038/nbt.2652 · DOI · Paper page
- 10.1534/genetics.110.117002 · DOI · Paper page
- Cui, 2011, Nat Biotechnol., 29, 64, 10.1038/nbt.1731 · DOI · Paper page
- 10.1073/pnas.1009424107 · DOI · Paper page
- Sung, 2013, Nat Biotechnol., 31, 23, 10.1038/nbt.2477 · DOI · Paper page
- 10.1073/pnas.1218721110 · DOI
- 10.1038/cr.2013.46 · DOI · Paper page
- 10.1371/journal.pone.0093806 · DOI · Paper page
- 10.1534/genetics.114.163667 · DOI · Paper page
- Yin, 2014, Nat Biotechnol., 32, 551, 10.1038/nbt.2884 · DOI · Paper page
- 10.1016/j.stem.2009.05.023 · DOI · Paper page
- 10.1038/nmeth.1323 · DOI · Paper page
- 10.1002/stem.718 · DOI · Paper page
- 10.1016/j.stem.2013.01.008 · DOI · Paper page
- 10.1038/nbt.1663 · DOI · Paper page
Cited by
Delivering CRISPR: a review of the challenges and approaches
Lino, C. A., Harper, J. C., Carney, J. P., & Timlin, J. A. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1474964 · Cited by 1,185
Base editing: advances and therapeutic opportunities
Porto, E. M., Komor, A. C., Slaymaker, I. M., & Yeo, G. W. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0084-6 · Cited by 476
Anemia: progress in molecular mechanisms and therapies
Sankaran, V. G., & Weiss, M. J. (2015) · Nature Medicine · doi:10.1038/nm.3814 · Cited by 281
Lancet Commission: Stem cells and regenerative medicine
Cossu, G., Birchall, M., Brown, T., De Coppi, P., Culme-Seymour, E., Gibbon, S., Hitchcock, J., Mason, C., Montgomery, J., Morris, S., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)31366-1 · Cited by 272
Ormond, K. E., Mortlock, D. P., Scholes, D. T., Bombard, Y., Brody, L. C., Faucett, W. A., Garrison, N. A., Hercher, L., Isasi, R., Middleton, A., et al. (2017) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2017.06.012 · Cited by 252
Self-citation
Metadata
- Authors
- Gupta, R. M., & Musunuru, K.
- Venue
- Journal of Clinical Investigation
- Published
- 2014-10-01
- Volume
- 124
- Issue
- 10
- Pages
- 4154-4161
- ISSN
- 0021-9738
- Cited by
- 492
- References
- 33
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9. https://app.cochat.ai/papers/10.1172/jci72992
- The paper
- Gupta, R. M., & Musunuru, K. (2014). Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9. Journal of Clinical Investigation. https://doi.org/10.1172/jci72992
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.